{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:02:40Z","timestamp":1780376560637,"version":"3.54.1"},"reference-count":152,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.reumae.2023.07.004","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T07:27:09Z","timestamp":1700897229000},"page":"533-548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis"],"prefix":"10.1016","volume":"19","author":[{"given":"Alejandro","family":"Balsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"D\u00edaz del Campo Fontecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Silva Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Valencia Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Nistal Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Le\u00f3n V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Vanesa","family":"Hern\u00e1ndez Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Corominas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"C\u00e1liz C\u00e1liz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Aguado Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Candelas Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Ibargoyen Roteta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Mart\u00ed Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Nieves","family":"Plana Farras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Pu\u00f1al Riob\u00f3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Tri\u00f1anes Pego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Villaverde Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2023.07.004_bib0005","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: Recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104410","article-title":"The role of registries in the treatment of rheumatoid arthritis with biologic disease-modifying anti-rheumatic drugs","volume":"148","author":"Pombo-Suarez","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.reumae.2023.07.004_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: A randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0030","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2023.07.004_bib0035","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.reumae.2023.07.004_bib0040","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.reuma.2011.05.002","article-title":"Consenso SER sobre la gesti\u00f3n de riesgo del tratamiento con terapias biol\u00f3gicas en pacientes con enfermedades reum\u00e1ticas","volume":"7","author":"G\u00f3mez Reino","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2023.07.004_bib0045","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12879-020-05082-8","article-title":"Adherence to guidelines across different specialties to prevent infections in patients undergoing immunosuppressive therapies","volume":"20","author":"Chadwick","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0055","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00431-022-04418-7","article-title":"Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening)","volume":"181","author":"Cuadros","year":"2022","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.reumae.2023.07.004_bib0060","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.reumae.2023.07.004_bib0065","series-title":"Vacunaci\u00f3n en grupos de riesgo de todas las edades y en determinadas situaciones. Ponencia de Programa y Riesgo de Vacunaciones","first-page":"119","author":"Limia","year":"2018"},{"key":"10.1016\/j.reumae.2023.07.004_bib0070","author":"Australian Health Ministers\u2019 Advisory Council"},{"key":"10.1016\/j.reumae.2023.07.004_bib0075","author":"Public Health Agency of Canada"},{"key":"10.1016\/j.reumae.2023.07.004_bib0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2013","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0085","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0095","article-title":"Efficacy and safety of JAK inhibitors for rheumatoid arthritis: A meta-analysis","volume":"11","author":"Wang","year":"2022","journal-title":"J Clin Med"},{"issue":"Suppl 9","key":"10.1016\/j.reumae.2023.07.004_bib0100","article-title":"The risk of venous thromboembolic events in patients with RA aged \u2265 50 years with \u2265 1 cardiovascular risk factor: Results from a phase 3b\/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]","volume":"73","author":"Charles-Schoeman","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0105","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: Results from the open-label, randomised controlled ORAL Surveillance trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0110","unstructured":"AEMPS. Inhibidores de la quinasa Janus para enfermedades inflamatorias cr\u00f3nicas: recomendaciones para minimizar los riesgos de reacciones adversas graves. 2022. Ref: MUH(FV), 8\/2022). Available from: https:\/\/www.aemps.gob.es\/informa\/inhibidores-de-la-quinasa-janus-para-enfermedades-inflamatorias-cronicas-recomendaciones-para-minimizar-los-riesgos-de-reacciones-adversas-graves\/."},{"key":"10.1016\/j.reumae.2023.07.004_bib0115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41584-022-00856-7","article-title":"Optimizing methotrexate withdrawal during COVID vaccination","volume":"18","author":"McHugh","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0120","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1080\/17512433.2016.1234374","article-title":"What are the dangers of biological therapy discontinuation or dose reduction strategies when treating rheumatoid arthritis?","volume":"9","author":"Atzeni","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s13063-022-06543-y","article-title":"Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: A study protocol for a non-inferiority randomized, controlled, single-blind trial","volume":"23","author":"Lei","year":"2022","journal-title":"Trials"},{"key":"10.1016\/j.reumae.2023.07.004_bib0130","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000352","article-title":"No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: A systematic literature review and meta-analysis","volume":"3","author":"Baradat","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2023.07.004_bib0135","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.amjmed.2014.06.012","article-title":"The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: A meta-analysis update of 44 trials","volume":"127","author":"Michaud","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.reumae.2023.07.004_bib0140","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/1756-185X.13596","article-title":"Infection risks of rituximab versus non-rituximab treatment for rheumatoid arthritis: A systematic review and meta-analysis","volume":"22","author":"Shi","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0145","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0150","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1007\/s10067-021-05686-8","article-title":"Efficacy and safety of jakinibs in rheumatoid arthritis: A systematic review and meta-analysis","volume":"40","author":"Yin","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13075-020-02188-x","article-title":"Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: A systematic analysis of the literature and meta-analysis","volume":"22","author":"Vinson","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2023.07.004_bib0160","first-page":"1","article-title":"Systematic review for the treatment of older rheumatoid arthritis patients informing the 2020 update of the Japan college of rheumatology clinical practice guidelines for the management of rheumatoid arthritis","author":"Sugihara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0165","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/ard.2010.148700","article-title":"Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: The ROSE study","volume":"71","author":"Yazici","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0170","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0175","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","article-title":"Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): A randomised, double-blind, parallel-group phase III trial","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0180","first-page":"937","article-title":"Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: An open-label phase 3 trial (MIRAI)","volume":"37","author":"D\u00f6rner","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0185","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-019-1992-x","article-title":"Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study","volume":"21","author":"Simon","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2023.07.004_bib0190","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/annrheumdis-2018-214367","article-title":"Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: A multidatabase cohort study","volume":"78","author":"Pawar","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0195","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/S2665-9913(19)30137-7","article-title":"Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: A multidatabase cohort study","volume":"2","author":"Pawar","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0200","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.gastrohep.2020.03.011","article-title":"Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020)","volume":"43","author":"Rodr\u00edguez","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0205","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4321\/S1130-01082010000900006","article-title":"Hepatitis B reactivation and current clinical impact","volume":"102","author":"Alvarez-Su\u00e1rez","year":"2010","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.reumae.2023.07.004_bib0210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7326\/0003-4819-112-5-381","article-title":"Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy","volume":"112","author":"Flowers","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.reumae.2023.07.004_bib0215","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/14740338.4.3.599","article-title":"Reactivation of hepatitis B virus with rituximab","volume":"4","author":"Tsutsumi","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.reumae.2023.07.004_bib0220","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/s10165-011-0458-z","article-title":"Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and\/or nonbiological disease-modifying antirheumatic drugs","volume":"21","author":"Mori","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0225","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/1756-185X.12359","article-title":"Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"19","author":"Nakamura","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0230","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00535-010-0367-5","article-title":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: Evaluation of both HBsAg-positive and HBsAg-negative cohorts","volume":"46","author":"Tamori","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0235","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/s10165-010-0337-z","article-title":"Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients","volume":"21","author":"Urata","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0240","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/1756-185X.13401","article-title":"Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs","volume":"22","author":"Watanabe","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.reumae.2023.07.004_bib0245","first-page":"S42","article-title":"Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: A retrospective analysis of 32 patients","volume":"75","author":"Ballanti","year":"2014","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.reumae.2023.07.004_bib0250","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2021-220774","article-title":"Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease","volume":"80","author":"Chen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0255","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy","volume":"70","author":"Lan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0260","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10067-013-2385-1","article-title":"Anti-TNF therapy in patients with HBV infection--analysis of 87 patients with inflammatory arthritis","volume":"33","author":"Ye","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0265","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3349\/ymj.2018.59.3.452","article-title":"Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: data from real-world experience","volume":"59","author":"Ahn","year":"2018","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.reumae.2023.07.004_bib0270","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13010","article-title":"Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: A prospective clinical observation","volume":"20","author":"Chen","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0275","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/1756-185X.13582","article-title":"Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation","volume":"22","author":"Chen","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0280","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1038\/s41598-020-59406-4","article-title":"Moderate risk of hepatitis B virus reactivation in HBsAg(-)\/HBcAb(+) carriers receiving rituximab for rheumatoid arthritis","volume":"10","author":"Kuo","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.reumae.2023.07.004_bib0285","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s10620-020-06725-1","article-title":"Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing tocilizumab-containing treatment","volume":"66","author":"Kuo","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.reumae.2023.07.004_bib0290","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/acr.22786","article-title":"Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection","volume":"68","author":"Padovan","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.reumae.2023.07.004_bib0295","first-page":"102","article-title":"Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: an observational, controlled, long-term study","volume":"36","author":"Papalopoulos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0300","first-page":"831","article-title":"Incidence and clinical characteristics of hepatitis B virus reactivation in HBsAg-negative\/HBcAb-positive patients receiving rituximab for rheumatoid arthritis","volume":"35","author":"Tien","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0305","doi-asserted-by":"crossref","first-page":"869","DOI":"10.3899\/jrheum.151105","article-title":"Low risk of hepatitis B virus reactivation in HBsAg-negative\/anti-HBc-positive carriers receiving rituximab for rheumatoid arthritis: a retrospective multicenter Italian study","volume":"43","author":"Varisco","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0310","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/1756-185X.14217","article-title":"Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib","volume":"24","author":"Wang","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0315","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001095","article-title":"Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis","volume":"6","author":"Harigai","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2023.07.004_bib0320","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0325","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reumae.2023.07.004_bib0330","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: Implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0335","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk factors for herpes zoster infection: a meta-analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0340","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1086\/368196","article-title":"Treatment and prevention of postherpetic neuralgia","volume":"36","author":"Dworkin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0345","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/acr.22815","article-title":"Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review","volume":"68","author":"Desai","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.reumae.2023.07.004_bib0350","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A systematic literature research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2023.07.004_bib0355","article-title":"Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results","author":"Combe","year":"2019","journal-title":"Abstract ACR\/ARP Annual Meeting"},{"key":"10.1016\/j.reumae.2023.07.004_bib0360","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2020-eular.277","article-title":"Efficacy and safety of Filgotinib in methotrexate-na\u00efve patients with rheumatoid arthritis: FINCH 3 52-week results","volume":"79","author":"Westhovens","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0365","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2014-206106","article-title":"Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0370","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): A double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0375","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: Results from a randomised, dose-finding study (DARWIN 1)","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2023.07.004_bib0380","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/acr.23824","article-title":"Risk of hospitalized infection and initiation of abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: A propensity score-matched cohort study","volume":"72","author":"Chen","year":"2020","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.reumae.2023.07.004_bib0385","doi-asserted-by":"crossref","first-page":"868","DOI":"10.55563\/clinexprheumatol\/pudtpo","article-title":"Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: A real-life multicentre study","volume":"39","author":"Guidelli","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0390","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/14397595.2016.1206507","article-title":"Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naive patients with rheumatoid arthritis: the FIRST Bio study","volume":"27","author":"Ishiguro","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0395","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a united states-based rheumatoid arthritis registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0400","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","article-title":"Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register","volume":"81","author":"Redeker","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0405","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3109\/14397595.2015.1101200","article-title":"RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database","volume":"26","author":"Torrente-Segarra","year":"2016","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0410","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0415","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0420","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0425","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.reumae.2023.07.004_bib0430","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0021-9681(78)90071-1","article-title":"Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis","volume":"31","author":"Isom\u00e4ki","year":"1978","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0435","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: A meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2023.07.004_bib0440","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: Results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0445","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1136\/ard.2005.045872","article-title":"Swedish registers to examine drug safety and clinical issues in RA","volume":"65","author":"Askling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0450","first-page":"4","article-title":"Spanish registry for adverse events of biological therapy in rheumatic diseases (BIOBADASER): State report, January 26th, 2006","volume":"3","author":"Descalzo","year":"2007","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2023.07.004_bib0455","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/CLEP.S99490","article-title":"The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO","volume":"8","author":"Ibfelt","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0460","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/msc.39","article-title":"The role of the British Society for Rheumatology Biologics Register (BSRBR) and the NICE guidelines for anti-TNF therapy","volume":"1","author":"Watson","year":"2003","journal-title":"Musculoskeletal Care"},{"key":"10.1016\/j.reumae.2023.07.004_bib0465","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1136\/ard.2004.031476","article-title":"Treatment continuation in patients receiving biological agents or conventional DMARD therapy","volume":"64","author":"Zink","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0470","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.berh.2019.03.011","article-title":"Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management","volume":"32","author":"De Cock","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0475","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13317-021-00153-5","article-title":"Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solipuram","year":"2021","journal-title":"Auto Immun Highlights"},{"key":"10.1016\/j.reumae.2023.07.004_bib0480","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10067-019-04865-y","article-title":"Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis","volume":"39","author":"Wang","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0485","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0490","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13075-017-1482-y","article-title":"The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs","volume":"19","author":"Cho","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2023.07.004_bib0495","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/rheumatology\/keaa330","article-title":"Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs-a Swedish cohort study of risks by time, drug and lymphoma subtype","volume":"60","author":"Hellgren","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0500","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5414\/CP203604","article-title":"Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"58","author":"Inose","year":"2020","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.reumae.2023.07.004_bib0505","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.reumae.2023.07.004_bib0510","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/annrheumdis-2016-209389","article-title":"Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0515","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1136\/annrheumdis-2017-211623","article-title":"Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: A European registries collaborative project","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0520","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/rheumatology\/key352","article-title":"Abatacept initiation in rheumatoid arthritis and the risk of cancer: A population-based comparative cohort study","volume":"58","author":"Montastruc","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0525","first-page":"26","article-title":"Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry","volume":"4","author":"Rahman","year":"2020","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-018-0050-7","article-title":"Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: An update from the Australian Rheumatology Association Database (ARAD) prospective cohort study","volume":"3","author":"Staples","year":"2019","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0535","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jamainternmed.2017.4332","article-title":"Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: A nationwide cohort study from Sweden","volume":"177","author":"Wadstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.reumae.2023.07.004_bib0540","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of malignancy: Results from the safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0545","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10067-014-2492-7","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"33","author":"Ungprasert","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0550","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","article-title":"Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A general population-based cohort study","volume":"39","author":"Ogdie","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.reumae.2023.07.004_bib0555","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/annrheumdis-2013-203380","article-title":"Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: A nationwide cohort study","volume":"73","author":"Chung","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0560","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/annrheumdis-2012-201669","article-title":"The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: A UK population-based outpatient cohort study","volume":"72","author":"Choi","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0565","first-page":"355","article-title":"Arterial and venous thromboembolic events during anti-TNF therapy: A study of 85 spontaneous reports in the period 2000-2006","volume":"19","author":"Petitpain","year":"2009","journal-title":"Biomed Mater Eng"},{"key":"10.1016\/j.reumae.2023.07.004_bib0570","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: A nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0575","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: A systematic review and meta-analysis.","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.reumae.2023.07.004_bib0580","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: Systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0585","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X19895492","article-title":"Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Xie","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0590","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2665-9913(19)30005-0","article-title":"Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): A randomised, phase 3b\/4, non-inferiority trial","volume":"1","author":"Cohen","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.reumae.2023.07.004_bib0595","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1136\/annrheumdis-2020-eular.2059","volume":"79","author":"Rubbert-Roth","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0600","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1136\/ard.2011.153536","article-title":"Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Davies","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0605","doi-asserted-by":"crossref","first-page":"539.e7","DOI":"10.1016\/j.amjmed.2014.11.025","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.reumae.2023.07.004_bib0610","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001013","article-title":"Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting","volume":"5","author":"Liang","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2023.07.004_bib0615","article-title":"The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study","volume":"12","author":"Moots","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.reumae.2023.07.004_bib0620","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.reumae.2023.07.004_bib0625","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/acr.23781","article-title":"Long-term safety of rituximab in rheumatoid arthritis: Analysis from the SUNSTONE registry","volume":"71","author":"Winthrop","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.reumae.2023.07.004_bib0630","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: A comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2023.07.004_bib0635","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","article-title":"Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: A population-based cohort study","volume":"61","author":"Desai","year":"2021","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0640","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0645","article-title":"The risk of venous thromboembolic events in patients with RA aged \u2265 50 years with \u2265 1 cardiovascular risk factor: Results from a phase 3b\/4 randomized safety study of tofacitinib vs TNF inhibitors","author":"Charles-Schoeman","year":"2021","journal-title":"ACR Convergence"},{"key":"10.1016\/j.reumae.2023.07.004_bib0650","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","article-title":"Upadacitinib in rheumatoid arthritis: A benefit-risk assessment across a phase III program","volume":"44","author":"Conaghan","year":"2021","journal-title":"Drug Safe"},{"key":"10.1016\/j.reumae.2023.07.004_bib0655","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1093\/rheumatology\/keaa858","article-title":"Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway","volume":"60","author":"Fitton","year":"2020","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0660","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2665-9913(20)30032-1","article-title":"Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: An updated integrated safety analysis","volume":"2","author":"Genovese","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0665","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002571","article-title":"Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors","volume":"8","author":"Weitz","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2023.07.004_bib0670","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bpobgyn.2017.08.006","article-title":"Epidemiology and burden of HPV-related disease","volume":"47","author":"Serrano","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0675","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00296-014-3157-1","article-title":"Human papillomavirus and chlamydia trachomatis infections in rheumatoid arthritis under anti-TNF therapy: An observational study","volume":"35","author":"Waisberg","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.reumae.2023.07.004_bib0680","first-page":"559","article-title":"Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"59","author":"Chadwick","year":"2020","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0685","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/kew012","article-title":"Risk of virus-associated cancer in female arthritis patients treated with biological DMARDs-A cohort study","volume":"55","author":"Cordtz","year":"2016","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0690","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/art.39689","article-title":"Biologic disease-modifying antirheumatic drugs and risk of high-grade cervical dysplasia and cervical cancer in rheumatoid arthritis: A cohort study","volume":"68","author":"Kim","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reumae.2023.07.004_bib0695","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"Kremer","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2023.07.004_bib0700","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000213","article-title":"Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab","volume":"2","author":"Rubbert-Roth","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.reumae.2023.07.004_bib0705","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1136\/annrheumdis-2015-208263","article-title":"Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden","volume":"75","author":"Wadstr\u00f6m","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.reumae.2023.07.004_bib0710","doi-asserted-by":"crossref","first-page":"56.e1","DOI":"10.1016\/j.anpedi.2018.10.006","article-title":"[Immunisation schedule of the Spanish Association of Paediatrics: 2019 recommendations]","volume":"90","author":"Moreno-P\u00e9rez","year":"2019","journal-title":"An Pediatr (Engl Ed)"},{"key":"10.1016\/j.reumae.2023.07.004_bib0715","series-title":"Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud Ministerio de Sanidad, Consumo y Bienestar Social. Vacunaci\u00f3n en poblaci\u00f3n adulta","year":"2018"},{"key":"10.1016\/j.reumae.2023.07.004_bib0720","unstructured":"Grupo de trabajo vacunaci\u00f3n en poblaci\u00f3n adulta y grupos de riesgo de la Ponencia de Programa y Registro de Vacunaciones. Vacunaci\u00f3n en grupos de riesgo de todas las edades y en determinadas situaciones. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad, Consumo y Bienestar Social, julio 2018."},{"key":"10.1016\/j.reumae.2023.07.004_bib0725","author":"Linertov\u00e1"},{"key":"10.1016\/j.reumae.2023.07.004_bib0730","unstructured":"Grupo de trabajo de Vacunaci\u00f3n frente a VPH en varones de la Ponencia de Programa y Registro de Vacunaciones. Comisi\u00f3n de Salud P\u00fablica del Consejo Interterritorial del Sistema Nacional de Salud. Ministerio de Sanidad. 2020. Available from: https:\/\/www.sanidad.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/comoTrabajamos\/docs\/Recomendaciones_vacunacion_VPHVarones.pdf."},{"key":"10.1016\/j.reumae.2023.07.004_bib0735","unstructured":"US Food and Drug Administration. Xeljanz XR (tofacitinib): Drug safety communication\u2014initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine. 2022. Available from: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/xeljanz-xeljanz-xr-tofacitinibdrug-safety-communication-initial-safety-trial-results-find-incre ased?utmmedium=email&utm source=govdelivery"},{"key":"10.1016\/j.reumae.2023.07.004_bib0740","unstructured":"EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders | European Medicines Agency (europa.eu). 2022. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic."},{"key":"10.1016\/j.reumae.2023.07.004_bib0745","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-022-00767-7","article-title":"Oral surveillance and JAK inhibitor safety: The theory of relativity","volume":"18","author":"Winthrop","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0750","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41584-022-00891-4","article-title":"JAK inhibitors: New indication and emerging safety data in 2022","volume":"19","author":"Nash","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.reumae.2023.07.004_bib0755","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: A multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.reumae.2023.07.004_bib0760","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","article-title":"Tofacitinib and risk of cardiovascular outcomes: Results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study","volume":"81","author":"Khosrow-Khavar","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574323001569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574323001569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:03:36Z","timestamp":1761879816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574323001569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":152,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2173574323001569"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2023.07.004","relation":{},"ISSN":["2173-5743"],"issn-type":[{"value":"2173-5743","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2023.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2023.07.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Reumatolog\u00eda y Colegio Mexicano de Reumatolog\u00eda. All rights reserved.","name":"copyright","label":"Copyright"}]}}